{"id":"NCT01306214","sponsor":"Boehringer Ingelheim","briefTitle":"Safety and Efficacy of BI 10773 as add-on to Insulin Regimen in Patients With Type 2 Diabetes Mellitus","officialTitle":"A Phase III, Randomized, Double-blind, Placebo-controlled, Parallel Group Safety and Efficacy Study of BI 10773 (10 mg and 25 mg Administered Orally Once Daily) During 52 Weeks in Patients With Type 2 Diabetes Mellitus and Insufficient Glycemic Control on MDI Insulin Regimen Alone or With Metformin","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-02","primaryCompletion":"2013-04","completion":"2013-04","firstPosted":"2011-03-01","resultsPosted":"2014-06-17","lastUpdate":"2014-06-17"},"enrollment":566,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes Mellitus, Type 2","Obesity"],"interventions":[{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"BI 10773","otherNames":[]},{"type":"DRUG","name":"BI 10773","otherNames":[]}],"arms":[{"label":"BI 10773 low dose","type":"EXPERIMENTAL"},{"label":"BI 10773 high dose","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This trial will evaluate use of BI 10773 as add-on to insulin regimen alone or with metformin in patients with typr 2 diabetes. Both lowering glucose and HbA1c and reducing the use of insulin in this population would provide significant new information for the BI 10773 use and would offer a potential new therapeutic option in this population.","primaryOutcome":{"measure":"Change From Baseline in HbA1c After 18 Weeks of Treatment","timeFrame":"Baseline and 18 weeks","effectByArm":[{"arm":"Placebo","deltaMin":-0.5,"sd":0.05},{"arm":"Empagliflozin 10 mg","deltaMin":-0.94,"sd":0.05},{"arm":"Empagliflozin 25 mg","deltaMin":-1.02,"sd":0.05}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"},{"comp":"OG000 vs OG002","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":103,"countries":["United States","Belgium","Bulgaria","Colombia","Czechia","Finland","France","Germany","Guatemala","Mexico","Peru","Russia","Spain","Ukraine"]},"refs":{"pmids":["35472672","24929430"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":22,"n":188},"commonTop":["Hypoglycaemia","Nasopharyngitis","Urinary tract infection","Diarrhoea","Back pain"]}}